End-of-day quote
Ho Chi Minh S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
66,600
VND
|
-0.15%
|
|
+4.06%
|
+15.83%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,621,924
|
2,500,377
|
2,059,339
|
1,823,192
|
1,427,299
|
1,996,829
|
Enterprise Value (EV)
1 |
2,275,913
|
2,141,711
|
1,826,569
|
1,512,572
|
974,595
|
1,407,268
|
P/E ratio
|
11.5
x
|
10.7
x
|
11.5
x
|
11.4
x
|
7.13
x
|
12.8
x
|
Yield
|
3.31%
|
3.47%
|
4.22%
|
4.76%
|
6.08%
|
-
|
Capitalization / Revenue
|
1.89
x
|
1.7
x
|
1.42
x
|
1.22
x
|
0.9
x
|
1.16
x
|
EV / Revenue
|
1.64
x
|
1.46
x
|
1.26
x
|
1.01
x
|
0.61
x
|
0.82
x
|
EV / EBITDA
|
7.76
x
|
7.25
x
|
7.98
x
|
7.19
x
|
3.84
x
|
6.96
x
|
EV / FCF
|
-22.7
x
|
42.8
x
|
-29.4
x
|
10.8
x
|
4
x
|
10
x
|
FCF Yield
|
-4.4%
|
2.34%
|
-3.4%
|
9.25%
|
25%
|
9.97%
|
Price to Book
|
2.32
x
|
2
x
|
1.57
x
|
1.33
x
|
0.98
x
|
1.31
x
|
Nbr of stocks (in thousands)
|
34,727
|
34,727
|
34,727
|
34,727
|
34,727
|
34,727
|
Reference price
2 |
75,500
|
72,000
|
59,300
|
52,500
|
41,100
|
57,500
|
Announcement Date
|
3/18/19
|
3/30/20
|
3/31/21
|
4/1/22
|
4/3/23
|
4/2/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,385,088
|
1,468,390
|
1,451,954
|
1,498,395
|
1,592,727
|
1,719,032
|
EBITDA
1 |
293,328
|
295,232
|
228,776
|
210,337
|
253,970
|
202,211
|
EBIT
1 |
263,924
|
266,947
|
203,176
|
186,405
|
234,484
|
183,443
|
Operating Margin
|
19.05%
|
18.18%
|
13.99%
|
12.44%
|
14.72%
|
10.67%
|
Earnings before Tax (EBT)
1 |
286,090
|
290,916
|
224,566
|
199,204
|
250,198
|
229,175
|
Net income
1 |
228,772
|
232,635
|
179,535
|
159,282
|
200,076
|
183,333
|
Net margin
|
16.52%
|
15.84%
|
12.37%
|
10.63%
|
12.56%
|
10.66%
|
EPS
2 |
6,588
|
6,699
|
5,170
|
4,587
|
5,761
|
4,487
|
Free Cash Flow
1 |
-100,216
|
50,029
|
-62,098
|
139,874
|
243,514
|
140,283
|
FCF margin
|
-7.24%
|
3.41%
|
-4.28%
|
9.33%
|
15.29%
|
8.16%
|
FCF Conversion (EBITDA)
|
-
|
16.95%
|
-
|
66.5%
|
95.88%
|
69.37%
|
FCF Conversion (Net income)
|
-
|
21.51%
|
-
|
87.82%
|
121.71%
|
76.52%
|
Dividend per Share
2 |
2,500
|
2,500
|
2,500
|
2,500
|
2,500
|
-
|
Announcement Date
|
3/18/19
|
3/30/20
|
3/31/21
|
4/1/22
|
4/3/23
|
4/2/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
346,011
|
358,667
|
232,770
|
310,620
|
452,704
|
589,561
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-100,216
|
50,029
|
-62,098
|
139,874
|
243,514
|
140,283
|
ROE (net income / shareholders' equity)
|
22%
|
19.5%
|
14%
|
11.9%
|
14.2%
|
12.3%
|
ROA (Net income/ Total Assets)
|
11.9%
|
11.1%
|
8.47%
|
7.55%
|
8.47%
|
6.22%
|
Assets
1 |
1,921,256
|
2,090,214
|
2,118,659
|
2,109,470
|
2,361,725
|
2,947,946
|
Book Value Per Share
2 |
32,526
|
36,060
|
37,877
|
39,336
|
42,028
|
43,784
|
Cash Flow per Share
2 |
2,289
|
2,833
|
3,096
|
2,458
|
1,367
|
3,292
|
Capex
1 |
41,930
|
35,203
|
14,258
|
6,114
|
10,565
|
7,301
|
Capex / Sales
|
3.03%
|
2.4%
|
0.98%
|
0.41%
|
0.66%
|
0.42%
|
Announcement Date
|
3/18/19
|
3/30/20
|
3/31/21
|
4/1/22
|
4/3/23
|
4/2/24
|
|
1st Jan change
|
Capi.
|
---|
| +15.83% | 91.3M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|